Amsterdam UMC Stichting — Sponsor Intelligence | 99 EU Trials

Filter these 99 trials by condition, phase, country and more.

Open in Search →

99 Registered trials

56 Recruiting

23 Completed trials

10 Countries active

125 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 18 Phase II/III: 4 Phase II: 24 Phase I/II: 9 Phase III/IV: 6 Phase IV: 35 Phase I (Other): 2 Phase I (FiH): 1

Oversight events:

1 temporary halt across 1 trial

View oversight register →

100%

23 of 23 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Fibrodysplasia ossificans progressiva 2 Colitis ulcerative 2 Crohn's disease 1 Heritable pulmonary arterial hypertension 1 Menopause 1 Pitt-Hopkins syndrome 1 Psoriasis 1 Vulval cancer stage I 1 Adrenocortical carcinoma 1 Bush-Francis catatonia rating scale 1 Complicated appendicitis 1 Lupus nephritis 1

Top IMPs

IPILIMUMAB 3 [18F]FLUORO-PEG-FOLATE 2 CAPECITABINE 2 DURVALUMAB 2 ESTRADIOL 2 FLORTAUCIPIR (18F) 2 FLUDEOXYGLUCOSE (18F) 2 HYDROCORTISONE 2 METHOTREXATE 2 PEMBROLIZUMAB 2 PROGESTERONE, MICRONISED 2 SODIUM CHLORIDE 2

All trials — page 4

99 total

Adjuvant therapy in high risk adrenocortical carcinoma (ADIUVO-2) Recruiting

2022-500013-32-01 Phase III 3 countries
Alkaline Phosphatase as treatment of Ischemia Reperfusion Injury to prevent delayed graft function or APhIRI II Recruiting

2024-515480-66-01 Phase II 1 country ALKALINE PHOSPHATASE, BOVINE
Immune-Related Rheumatological and neurological Adverse Events study. Recruiting

2024-516631-27-00 Phase II 1 country FLUDEOXYGLUCOSE (18F); IPILIMUMAB; NIVOLUMAB; NIVOLUMAB, RELATLIMAB; PEMBROLIZUM…
The efficacy of the addition of TRAstuzumab and Pertuzumab to neoadjuvant chemoradiation: a randomized multi-center study in resectable HER2… Recruiting

2024-513797-22-00 Phase III 1 country PERTUZUMAB; TRASTUZUMAB
Prevention of the return of nephrotic syndrom in children by adding levamisole to prednisolone treatment Ended

2024-517467-23-00 Phase III 1 country LEVAMISOLE HYDROCHLORIDE
Trial Examining Methods for Antidepressant Discontinuation (TEMPO) Ended

2024-511997-66-00 Phase IV 1 country
Intravenous immunoglobulin and prednisone vs. prednisone in newly diagnosed myositis: a double blind randomized clinical trial Ended

2024-516057-42-00 Phase II 1 country HUMAN NORMAL IMMUNOGLOBULIN; SODIUM CHLORIDE
Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS) Ended

2024-513105-31-00 Phase IV 1 country NATALIZUMAB
Personalized dosing of ocrelizumab in MS Ended

2024-513193-22-00 Phase III/IV 1 country OCRELIZUMAB
Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteremia (SAFE-trial) Ended

2024-515398-90-01 Phase III 1 country CEFAZOLIN SODIUM; CLINDAMYCIN; FLUCLOXACILLIN SODIUM MONOHYDRATE
A clinical trial to judge the safety, tolerability and effects on abnormal bone formation of reseach medication AZD 0530 (sarcatinib) in pat… Ended

2024-515186-33-00 Phase II 2 countries SARACATINIB
TURN-COVID Biobank: The Dutch cohort study for the evaluation of the use of neutralizing monoclonal antibodies and other antiviral agents ag… Ended

2024-515263-60-00 Phase IV 1 country CASIRIVIMAB; CILGAVIMAB; NIRMATRELVIR; SOTROVIMAB
DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTA… Ended

2024-518985-29-02 Phase I (FiH) 1 country LUTETIUM (177LU) ZADAVOTIDE GURAXETAN; RADIUM RA 223 DICHLORIDE
PARADOX study Ended

2024-515278-28-00 Phase IV 1 country OXYGEN
Dasatinib and quercetin, a combination of senolytics to treat fibrotic non-alcoholic fatty liver disease; The TRUTH study Ended

2024-517593-21-00 Phase II 1 country
HepBTer: From fungus to virus, a phase 2a clinical trial investigating the safety and efficacy of terbinafine in chronic hepatitis B patient… Ended

2024-514888-25-00 Phase II 1 country TERBINAFINE
Treating Leg Symptoms in Woman with X-ALD Ended

2024-518989-27-01 Phase IV 1 country PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE
MERCURI-2 Ended

2024-515260-31-00 Phase IV 1 country DAPAGLIFLOZIN
Clemastine fumarate as remyelinating treatment in internuclear ophthalmoparesis and multiple sclerosis Ended

2024-513099-17-00 Phase III 1 country CLEMASTINE; FAMPRIDINE
DIONYSIUS Ended

2024-511743-26-00 Phase IV 2 countries
PURE Ended

2024-515542-16-03 Phase IV 1 country TACROLIMUS
Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN) Ended

2024-516581-11-00 Phase III 1 country CARBOPLATIN; PACLITAXEL; PEMBROLIZUMAB; PEMETREXED
Medical research to compare the effectiveness of infliximab injections alone or in combination with immunosuppressive drugs in the treatment… Ended

2024-517171-20-00 Phase IV 1 country INFLIXIMAB
Effect of citalopram on chest pain in patients with achalasia. Ended

2024-517701-81-01 Phase IV 1 country CITALOPRAM

Showing 73–96 of 99 trials

← All sponsors A–Z